Market Size of Immune Checkpoint Inhibitors Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 18.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Immune Checkpoint Inhibitors Market Analysis
The immune checkpoint inhibitors market is anticipated to register a CAGR of 18% during the forecast period.
The sudden outbreak of the pandemic had a significant effect on cancer research, which affected the immune checkpoint inhibitors market. For instance, the Lancet article published in December 2021 mentioned that cancer research had been inconsistent, mostly taking place in high-income settings and some middle-income settings such as China and India. Furthermore, the work has largely been undertaken without substantial financial support from major cancer research funders. Thus, the above-mentioned factors are expected to have a significant impact on the growth of the market.
The primary factor attributed to the growth of the market is a steep rise in the global prevalence of various types of cancers, coupled with a steep increase in the geriatric population around the world. The IARC Report published in 2020 estimated the incidence and mortality of 36 cancer in 185 countries. It reported that there were an estimated 19,292,789 new cancer cases diagnosed in 2020, and about 9,958,133 people died due to cancer all over the world. Of the total diagnosed cancer cases, 10,065,305 cases were reported in males, and 9,227,484 cases were reported in females. The incidence of cancer cases in males is expected to reach 15,585,096 by 2040. The number is anticipated to reach 13,302,846 in females by 2040. Such an increasing incidence of cancer among the global population is expected to drive the growth of the market. Thus, the rise in the patient pool, increased awareness among the people, and earlier detection of cancer using technologically advanced screening procedures are likely to boost the immune checkpoint inhibitors market's growth during the forecast period.
However, a higher risk of complications associated with expensive oncology treatment is expected to restrain the growth of the market over the forecast period.
Immune Checkpoint Inhibitors Industry Segmentation
As per the scope of the report, immune checkpoint inhibitors are anticancer drugs used in immunotherapy, which enhance the immune response to detect and target cancer cells. These drugs are widely accepted as a standard treatment for advanced-stage cancers due to their proven efficiency and positive patient responses with a lower incidence of side effects compared to conventional chemotherapy.
The immune checkpoint inhibitors market is segmented by type of inhibitors (CTLA-4 inhibitors, PD-1 inhibitors, and other types of inhibitors), application (Hodgkin lymphoma, kidney cancer, melanoma, non-small cell lung cancer, and other applications), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Type of Inhibitors | |
| CTLA-4 Inhibitors | |
| PD-1 Inhibitors | |
| Other Types of Inhibitors |
| By Application | |
| Hodgkin Lymphoma | |
| Kidney Cancers | |
| Melanoma | |
| Non-small Cell Lung Cancer | |
| Other Applications |
| By Distribution Channel | |
| Hospital Pharmacies | |
| Retail Pharmacies | |
| Online Pharmacies |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Immune Checkpoint Inhibitors Market Size Summary
The immune checkpoint inhibitors market is poised for significant growth, driven by the increasing global prevalence of cancer and the expanding geriatric population. Despite challenges posed by the pandemic, which disrupted cancer research and funding, the market is expected to benefit from advancements in cancer detection and heightened awareness. The market's expansion is further supported by the dominance of the PD-1 inhibitors segment, fueled by ongoing research, product approvals, and the widespread prescription of drugs like nivolumab and pembrolizumab. Collaborative efforts among key players to develop new immune checkpoint inhibitors are also anticipated to enhance market revenue.
North America is projected to maintain a substantial share of the immune checkpoint inhibitors market, attributed to the high incidence of chronic diseases and robust regulatory approvals. The region's market growth is bolstered by the presence of major industry players and significant investments in research and development. The competitive landscape is characterized by strategic mergers, acquisitions, and research collaborations among leading companies such as Bristol Myers Squibb, AstraZeneca, and Merck & Co. These activities aim to address unmet medical needs and expand the therapeutic applications of existing drugs, thereby driving the market forward.
Immune Checkpoint Inhibitors Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Investments in R&D and Clinical Trials by the Biopharmaceutical Industry to Develop these Products
-
1.2.2 Increased Product Approvals by Regulatory Authorities and Special Designations for New Drug Molecules
-
-
1.3 Market Restraints
-
1.3.1 Higher Risk of Complications Associated with the Expensive Oncology Treatment
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
2.1 By Type of Inhibitors
-
2.1.1 CTLA-4 Inhibitors
-
2.1.2 PD-1 Inhibitors
-
2.1.3 Other Types of Inhibitors
-
-
2.2 By Application
-
2.2.1 Hodgkin Lymphoma
-
2.2.2 Kidney Cancers
-
2.2.3 Melanoma
-
2.2.4 Non-small Cell Lung Cancer
-
2.2.5 Other Applications
-
-
2.3 By Distribution Channel
-
2.3.1 Hospital Pharmacies
-
2.3.2 Retail Pharmacies
-
2.3.3 Online Pharmacies
-
-
2.4 Geography
-
2.4.1 North America
-
2.4.1.1 United states
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia-Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
Immune Checkpoint Inhibitors Market Size FAQs
What is the current Immune Checkpoint Inhibitors Market size?
The Immune Checkpoint Inhibitors Market is projected to register a CAGR of 18% during the forecast period (2024-2029)
Who are the key players in Immune Checkpoint Inhibitors Market?
Bristol Myers Squibb Company, Regeneron Pharmaceuticals Inc, AstraZeneca plc, F. Hoffmann-La Roche AG and Merck & Co Inc are the major companies operating in the Immune Checkpoint Inhibitors Market.
